Recaticimab in adult heterozygous familial hypercholesterolaemia (REMAIN-3): a multicentre, randomized, double-blind, placebo-controlled Phase 3 study
Year: 2025
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Cardiovascular Research
DOI: 10.1093/cvr/cvaf155
Authors: Liwen Li, Yujie Zhou, Chanjuan Deng, Jianlong Sheng, Daoquan Peng, Zhiyu Ling, Luya Wang, Cuilian Dai, Kai Huang, Qiufang Lian, Zaixin Yu, Haibo Yang, Yuying Hu, YuGang Dong, Nan Wang, Zhen Wang, Wei Zhang, Xuebin Han, Zhuhua Yao, Qiyun Liu, Yingzi Liang, Biao Xu, Ying Wang, Tingyan Zhong, Jiyan Chen
Institutions: Guangdong Provincial People's Hospital, Capital Medical University, Beijing Anzhen Hospital, Jiangsu Hengrui Medicine (China), Anhui Medical University, Second Affiliated Hospital of Anhui Medical University, Second Xiangya Hospital of Central South University, Second Affiliated Hospital of Chongqing Medical University, Beijing Chuiyangliu Hospital, Tsinghua University, Xiamen University, Wuhan Union Hospital, Huazhong University of Science and Technology, Yan'an University, Central South University, Xiangya Hospital Central South University, First Affiliated Hospital of Zhengzhou University, Sun Yat-sen University, The First Affiliated Hospital, Sun Yat-sen University, Gansu Provincial Hospital, Hebei Medical University, First Affiliated Hospital of Hebei Medical University, Jiangsu Province Hospital, Shanxi Cardiovascular Hospital, ShenZhen People’s Hospital, Second Hospital of Tianjin Medical University, Tianjin Medical University, Nanjing University
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Jiangsu Hengrui Medicine
OpenAlex ID: W4414012304